News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Oncolytic measles virus strains in the treatment of gliomas.


Posted on: 01/18/2008

Expert Opin Biol Ther. 2008 Feb;8(2):213-20.


Oncolytic measles virus strains in the treatment of gliomas.

Allen C, Paraskevakou G, Liu C, Iankov ID, Zollman P, Galanis E.

1Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 2511 ; +1 507 284 1803 ; galanis.evanthia@mayo.edu , 2Mayo Clinic, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.

Background: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. Objective: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. Methods: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. Results/conclusions: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.

PMID: 18194077 [PubMed - in process]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740